Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura: A chronic myelogenous leukemia case treated with interferon-α

Acta Haematologica

Volumn 113, Issue 3, 2005, Pages 198-203

  Sugimoto, Takeshi ^a   Saigo, Katsuyasu ^b,c   Shin, Tomohiro ^c   Kaneda, Yohji ^c   Manabe, Nobuya ^c   Narita, Hiroko ^c   Wakuya, Jun ^c   Imoto, Shion ^a   Murayama, Tohru ^a   Matsumoto, Masanori ^d   Fujimura, Yoshihiro ^d   Nishimura, Ryuichiro ^a   Koizumi, Tamio ^a   Kumagai, Shunichi ^b  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

^c Kobe Kyodo Hospital   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic myelogenous leukemia; Interferon ; Thrombotic thrombocytopenic purpura; Von Willebrand factor cleaving protease

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; PREDNISOLONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; KIDNEY FAILURE; LABORATORY TEST; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE;

ADAM PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; METALLOENDOPEPTIDASES; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; STEROIDS;

EID: 20844452224     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084451     Document Type: Article

References (36)

1. Jonasch E, Haluska FG: Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55.
2. Tothova E, Kafkova A, Stecova N, Fricova M, Guman T, Svorcova E: Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. Neoplasma 2002;49:91-94.
3. Medina PJ, Sipols JM, George JN: Drug-associated thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Curr Opin Hematol 2001;8:286-293.
4. Pisoni R, Ruggenenti P, Remuzzi G: Drug-induced thrombotic microangiopathy: Incidence, prevention and management. Drug Saf 2001;24:491-501.
5. Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH: Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003;44:471-475.
6. Zuber J, Martinez F, Droz D, Oksenhendler E, Legendre C; Groupe D'stude Des Nephrologues D'ile-de-France (GENIF): Alpha-interferon-associated thrombotic microangiopathy: A clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 2002;81:321-331.
7. Badid C, McGregor B, Faivre JM, Guerard A, Juillard L, Fouque D, Laville M: Renal thrombotic microangiopathy induced by interferon-alpha. Nephrol Dial Transplant 2001;16:846-848.
8. Cardineau E, Le Goff C, Henri P, Reman O, Lobbedez T, Hurault de Ligny B, Leporrier M, Ryckelynck JP: Nephropathies caused by interferon alpha: Apropos of 2 cases. Rev Med Interne 1995;16:691-695.
9. Harvey M, Rosenfeld D, Davies D, Hall BM: Recombinant interferon alpha and hemolytic uremic syndrome: Cause or coincidence? Am J Hematol 1994;46:152-153.
10. Honda K, Ando A, Endo M, Shimizu K, Higashihara M, Nitta K, Nihei H: Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia. Am J Kidney Dis 1997;30:123-130.
11. Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, van Ypersele de Strihou C: Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b. Nephrol Dial Transplant 1995;10:111-113.
12. Kobayashi H, Utsunomiya Y, Miyazaki Y, Tokutome G, Kawamura T, Hashimoto T, Sakai T, Takahashi S, Tojyo A, Asano S: Case of chronic myelogenous leukemia with hemolytic-uremic-syndrome like kidney during long-term interferon-alpha therapy. (Japanese, abstract in English) Nippon Naika Gakkai Zasshi 1997;86:1259-1261.
13. Lacotte L, Thierry A, Delwail V, Dreyfus B, Guilhot F: Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia. Acta Haematol 2000;102:160-162.
14. Lipton JH, Minden M: CML may not be part of HUS. Am J Hematol 1995;49:100-101.
15. Magee CC, Abraham K, Farrell J, Dorman T, Walshe JJ: Renal thrombotic microangiopathy associated with interferon-alpha treatment of chronic myeloid leukemia. Am J Kidney Dis 2000;36:E5.
16. Ohashi N, Yonemura K, Sugiura T, Isozaki T, Togawa A, Fujigaki Y, Yamamoto T, Hishida A: Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha. Am J Kidney Dis 2003;41:E10.
17. Rachmani R, Avigdor A, Youkla M, Raanani P, Zilber M, Ravid M, Ben-Bassat I: Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha: A report of two successfully treated patients. Acta Haematol 1998;100:204-206.
18. Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM: Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: Coincidence or true side effect? Cancer 1999;85:2583-2588.
19. Schlaifer D, Dumazer P, Spenatto N, Mignon-Conte M, Brousset P, Lumbroso C, Cooper M, Muller C, Huguet F, Attal M, Laurent G, Pris J: Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Am J Hematol 1994;47:254-255.
20. Shammas F, Meyer P, Heikkila R, Apeland T, Goransson L, Berland J, Kjellevold K: Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea. Acta Haematol 1997;97:184-186.
21. Vacher-Coponat H, Opris A, Daniel L, Harle JR, Veit V, Olmer M: Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha-interferon. Nephrol Dial Transplant 1999;14:2469-2471.
22. Studt JD, Kremer Hovinga JA, Alberio L, Bianchi V, Lammle B: Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: Diagnostic experience 2001/2002 of a single research laboratory. Swiss Med Wkly 2003;133:325-332.
23. Saigo K, Jiang M, Tanaka C, Fujimoto K, Kobayashi A, Nozu K, Iijima K, Ryo R, Sugimoto T, Imoto S, Kumagai S: Usefulness of automatic detection of fragmented red cells using a hematology analyzer for diagnosis of thrombotic microangiopathy. Clin Lab Haematol 2002;24:347-351.
24. Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, Funato M, Matsui T, Titani K, Yagi H, Matsumoto M, Fujimura Y: Upshaw-Schulman syndrome revisited: A concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 2001;74:101-108.
25. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
26. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-692.
27. Creput C, Auffret N, Samuel D, Jian R, Hill G, Nochy D: Cutaneous thrombotic microangiopathy during treatment with alpha-interferon for chronic hepatitis C. J Hepatol 2002;37:871-872.
28. Iyoda K, Kato M, Nakagawa T, Kakiuchi Y, Sugiyasu Y, Fujii E, Fujimoto K, Michida T, Kaneko A, Hayashi N, Yamamoto K, Kurosawa K, Ikeda M, Masuzawa M: Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C. J Gastroenterol 1998;33:588-592.
29. Ubara Y, Hara S, Takedatu H, Katori H, Yamada K, Yoshihara K, Matsushita Y, Yokoyama K, Takemoto F, Yamada A, Takagawa R, Endo Y, Hara M, Koida I, Kumada H: Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C. Nephron 1998;80:107-108.
30. Stratta P, Canavese C, Dogliani M, Thea A, Degani G, Mairone L, Vercellone A: Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia. Ren Fail 1993;15:559-561.
31. George JN, Sadler JE, Lammle B: Platelets: Thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2002;1:315-334.
32. Tsai HM, Lian EC: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
33. Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y: The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004;41:68-74.
34. van der Plas RM, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ, Fijnheer R: von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999;93:3798-3802.
35. George JN, Vesely SK, Terrell DR: The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: A community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004;41:60-67.
36. Gunsilius E, Duba HC, Petzer AL, Kahler CM, Grunewald K, Stockhammer G, Gabl C, Dirnhofer S, Clausen J, Gastl G: Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000;355:1688-1691.